Skip to content
Menu

Ensysce Biosciences, Inc. ENSC

Full chart Compare
Set alert

Price alert · ENSC

All alert types
0.36 USD 0.00 (-0.17%)

Regular-session close

0.39 +0.03 +8.33%

After hours · Nov 20, 4:00 PM ET

0.3593 Day range 0.3699
0.23 52-week range 1.85
YTD
-60.87%
1 year
-77.64%

5D -0.0594 (-14.14%)

0.37500.40000.4250FriMonTueWedThu0.3606
Market cap
7.00M
Revenue (ttm)
1.44M
EPS (ttm)
-7.51
Shares out
1.30M
Forward P/E
-9.08
YTD return
-60.87%
1-year return
-77.64%
50-day average
7.25
Volume
79.59K
Avg volume
504.35K
Open
0.36
Previous close
0.3606
Day's range
0.3593 – 0.3699
52-week range
0.23 – 1.85
Beta
0.64
Price target
102.00 (+28233.3%)

Key statistics

200-day average
7.64
Enterprise value
5.09M
Price / sales
7.50
Revenue growth
-62.90%
Free cash flow
-5.39M
Total cash
1.04M
Total debt
454.46K
Return on equity
-427.89%
Short % of float
45.08%

Fundamental scorecard

4 of 25 checks passed on ENSC’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
ENSC Revenue — quarterly 0
ENSC Net income — quarterly -82.11M
ENSC EPS — quarterly -4.52

Earnings

ENSC recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 12, 2024Sep 1, 2024-4.501.05+5.55+123.33%
Aug 14, 2024Jun 1, 2024-5.85-3.30+2.55+43.59%
Aug 14, 2024Jun 1, 2024-5.85———
May 10, 2024Mar 1, 2024-13.49-8.25+5.24+38.84%
May 10, 2024Mar 1, 2024-13.49———
Mar 15, 2024Dec 1, 2023-12.89-16.94-4.05-31.42%

Upgrades / downgrades

ENSC analyst upgrades and downgrades
DateFirmActionFromTo
Sep 25, 2023HC Wainwright & Co.mainBuyBuy
Jul 3, 2023HC Wainwright & Co.init—Buy

About Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
ensysce.com

News

Your note

Sign in to keep a note on ENSC — it syncs with the Stock Master app.

Insider holders

ENSC insider holders
InsiderRelationLatest transactionDateShares held
GOWER ROBERT GDirectorPurchaseMar 1, 20231,222,680

Institution ownership

ENSC institution ownership
Holder% heldSharesValueReported
Sabby Management, LLC0.40%77,507640.21KSep 29, 2024
Anson Funds Management LP0.33%65,568541.59KSep 29, 2024
UBS Group AG0.04%7,51262.05KSep 29, 2024
Geode Capital Management, LLC0.02%3,07125.37KSep 29, 2024
Citadel Advisors Llc0.01%1,57413.00KSep 29, 2024
HRT Financial LP0.01%1,57112.98KSep 29, 2024

Fund ownership

ENSC fund ownership
Holder% heldSharesValueReported
Fidelity Extended Market Index Fund0.01%2,82923.37KOct 30, 2024
Vanguard Extended Market Index Fund0.01%1,21210.01KSep 29, 2024
Fidelity Series Total Market Index Fund0.00%1431.18KOct 30, 2024